Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy, such as doxorubicin, ifosfamide, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Chemoprotective drugs, such as dexrazoxane, may protect normal cells from the side effects of chemotherapy. Giving combination chemotherapy together with dexrazoxane before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This phase II trial is studying how well giving combination chemotherapy together with dexrazoxane followed by surgery and radiation therapy works in treating patients with advanced soft tissue sarcoma or recurrent bone sarcoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: City of Hope Medical Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Dexrazoxane; Doxorubicin; Ifosfamide; Irinotecan; Isophosphamide mustard; Liposomal doxorubicin; Razoxane

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of 1 of the following:

• Primary soft tissue sarcoma at high-risk* for recurrence, meeting any of the following criteria:

• Previously untreated locally advanced, nonmetastatic disease

• Advanced (metastatic) disease not amenable to standard or higher priority investigational neoadjuvant therapies

• Recurrent bone sarcoma (e.g., osteogenic sarcoma, Ewing sarcoma, or peripheral neuroectodermal tumor)

• Must have advanced locally recurrent or metastatic disease NOTE: *High-risk is defined as high-grade, deep to fascia, and > 5 cm in greatest dimension

• Measurable or nonmeasurable disease is not required

• Pre-chemotherapy consultation with surgery and radiation oncology is required for formulation of loco-regional therapy

• No gastrointestinal stromal cell sarcoma

• No alveolar soft part sarcoma

• No symptomatic brain metastases

• No requirement for anticonvulsant or corticosteroid therapy

PATIENT CHARACTERISTICS:

• Karnofsky performance status 70-100%

• Life expectancy ≥ 2 months

• Absolute neutrophil count ≥ 2,000/mm^3

• Platelet count > 120,000/mm^3

• Creatinine clearance > 50 mL/min

• Serum bilirubin ≤ 1.5 mg/dL

• SGOT or SGPT ≤ 2.5 times upper limit of normal

• Serum albumin ≥ 2.5 mg/dL

• LVEF ≥ 50% by MUGA scan

• Not pregnant or nursing

• Fertile patients must use effective contraception

• No concurrent nonmalignant illness (e.g., cardiovascular, pulmonary, or CNS disease) that is poorly controlled with currently available treatment or is of such severity that the investigators deem it unwise for the patient to enter the study

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No prior chemotherapy for recurrent (local or metastatic) soft tissue sarcoma

• Prior chemotherapy for recurrent bone sarcoma allowed provided the total dose of doxorubicin hydrochloride is ≤ 300 mg/m^2

• No prior radiotherapy to > 25% of bone marrow

• At least 3 weeks since prior radiotherapy or chemotherapy